Temozolomide (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Temozolomide" in Italian language version.

refsWebsite

Global rank Italian rank

4^th place

9^th place

2^nd place

7^th place

799^th place

22^nd place

2web.archive.org

1^st place

1^st place

2torrinomedica.it

low place

2,002^nd place

low place

low place

2,374^th place

1,283^rd place

1agenziafarmaco.gov.it

low place

1,603^rd place

agenziafarmaco.gov.it

Nota Informativa Importante su Temodal (temozolomide) (12/12/2013), su agenziafarmaco.gov.it. URL consultato il 15 dicembre 2013.

doi.org

dx.doi.org

Stupp R, Mason WP, van den Bent MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, in N. Engl. J. Med., vol. 352, n. 10, marzo 2005, pp. 987–96, DOI:10.1056/NEJMoa043330, PMID 15758009.
Stupp R, Hegi ME, Mason WP, et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, in Lancet Oncol., vol. 10, n. 5, maggio 2009, pp. 459–66, DOI:10.1016/S1470-2045(09)70025-7, PMID 19269895.
Glas M, Happold C, Rieger J, et al., Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide, in J. Clin. Oncol., vol. 27, n. 8, marzo 2009, pp. 1257–61, DOI:10.1200/JCO.2008.19.2195, PMID 19188676.
Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ, Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma, in CA Cancer J Clin, vol. 60, n. 3, 2010, pp. 166–93, DOI:10.3322/caac.20069, PMC 2888474, PMID 20445000.
van den Bent MJ, Dubbink HJ, Sanson M, et al., MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951, in J. Clin. Oncol., vol. 27, n. 35, dicembre 2009, pp. 5881–6, DOI:10.1200/JCO.2009.24.1034, PMC 2793037, PMID 19901104.
Bromberg JE, van den Bent MJ, Oligodendrogliomas: molecular biology and treatment, in Oncologist, vol. 14, n. 2, febbraio 2009, pp. 155–63, DOI:10.1634/theoncologist.2008-0248, PMID 19182242.
Guida M, Cramarossa A, Fistola E, et al., High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study, in J Transl Med, vol. 8, 2010, p. 115, DOI:10.1186/1479-5876-8-115, PMC 2992498, PMID 21067582.
Su Y, Amiri KI, Horton LW, et al., A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets, in Clin. Cancer Res., vol. 16, n. 1, gennaio 2010, pp. 348–57, DOI:10.1158/1078-0432.CCR-09-2087, PMID 20028756.
Clark JI, Moon J, Hutchins LF, et al., Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508, in Cancer, vol. 116, n. 2, gennaio 2010, pp. 424–31, DOI:10.1002/cncr.24739, PMC 2811758, PMID 19918923.
Glaspy J, Atkins MB, Richards JM, et al., Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma, in Cancer, vol. 115, n. 22, novembre 2009, pp. 5228–36, DOI:10.1002/cncr.24576, PMID 19728370.
Augustine CK, Yoo JS, Potti A, et al., Genomic and molecular profiling predicts response to temozolomide in melanoma, in Clin. Cancer Res., vol. 15, n. 2, gennaio 2009, pp. 502–10, DOI:10.1158/1078-0432.CCR-08-1916, PMID 19147755.
Meije Y, Lizasoain M, García-Reyne A, et al., Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review, in Clin. Infect. Dis., vol. 50, n. 12, giugno 2010, pp. e73–6, DOI:10.1086/653011, PMID 20455691.
Liu R, Wang X, Ma B, Yang K, Zhang Q, Tian J, Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis, in Anticancer Drugs, vol. 21, n. 1, gennaio 2010, pp. 120–8, DOI:10.1097/CAD.0b013e32833304c5, PMID 19881333.
Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K, Temozolomide for high grade glioma, in Cochrane Database Syst Rev, n. 4, 2008, pp. CD007415, DOI:10.1002/14651858.CD007415, PMID 18843749.
Boogerd W, de Gast GC, Dalesio O, Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?, in Cancer, vol. 109, n. 2, gennaio 2007, pp. 306–12, DOI:10.1002/cncr.22411, PMID 17149755.
Stupp R, Tonn JC, Brada M, Pentheroudakis G, High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, in Ann. Oncol., 21 Suppl 5, maggio 2010, pp. v190–3, DOI:10.1093/annonc/mdq187, PMID 20555079.
(FR) Tilleul P, Brignone M, Hassani Y, et al., [Prescription guidebook for temozolomide usage in brain tumors], in Bull Cancer, vol. 96, n. 5, maggio 2009, pp. 579–89, DOI:10.1684/bdc.2009.0865, PMID 19467988.

nejm.org

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma — NEJM, su nejm.org. URL consultato il 17 gennaio 2011.

nih.gov

ncbi.nlm.nih.gov

Nishikawa R, Standard therapy for glioblastoma--a review of where we are, in Neurol. Med. Chir. (Tokyo), vol. 50, n. 9, 2010, pp. 713–9, PMID 20885105.
Dresemann G, Temozolomide in malignant glioma, in Onco Targets Ther, vol. 3, 2010, pp. 139–46, PMC 2939767, PMID 20856849.
Stupp R, Mason WP, van den Bent MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, in N. Engl. J. Med., vol. 352, n. 10, marzo 2005, pp. 987–96, DOI:10.1056/NEJMoa043330, PMID 15758009.
Stupp R, Hegi ME, Mason WP, et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, in Lancet Oncol., vol. 10, n. 5, maggio 2009, pp. 459–66, DOI:10.1016/S1470-2045(09)70025-7, PMID 19269895.
Glas M, Happold C, Rieger J, et al., Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide, in J. Clin. Oncol., vol. 27, n. 8, marzo 2009, pp. 1257–61, DOI:10.1200/JCO.2008.19.2195, PMID 19188676.
Omar AI, Mason WP, Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas, in Core Evid, vol. 4, 2010, pp. 93–111, PMC 2899776, PMID 20694068.
Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ, Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma, in CA Cancer J Clin, vol. 60, n. 3, 2010, pp. 166–93, DOI:10.3322/caac.20069, PMC 2888474, PMID 20445000.
Spena G, Garbossa D, Barletta L, Prevost C, Versari P, Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection -case report-, in Neurol. Med. Chir. (Tokyo), vol. 50, n. 5, 2010, pp. 410–3, PMID 20505301.
van den Bent MJ, Dubbink HJ, Sanson M, et al., MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951, in J. Clin. Oncol., vol. 27, n. 35, dicembre 2009, pp. 5881–6, DOI:10.1200/JCO.2009.24.1034, PMC 2793037, PMID 19901104.
Lamoral-Theys D, Le Mercier M, Le Calvé B, et al., Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells, in Neoplasia, vol. 12, n. 1, gennaio 2010, pp. 69–79, PMC 2805885, PMID.
Bromberg JE, van den Bent MJ, Oligodendrogliomas: molecular biology and treatment, in Oncologist, vol. 14, n. 2, febbraio 2009, pp. 155–63, DOI:10.1634/theoncologist.2008-0248, PMID 19182242.
Guida M, Cramarossa A, Fistola E, et al., High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study, in J Transl Med, vol. 8, 2010, p. 115, DOI:10.1186/1479-5876-8-115, PMC 2992498, PMID 21067582.
Su Y, Amiri KI, Horton LW, et al., A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets, in Clin. Cancer Res., vol. 16, n. 1, gennaio 2010, pp. 348–57, DOI:10.1158/1078-0432.CCR-09-2087, PMID 20028756.
Clark JI, Moon J, Hutchins LF, et al., Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508, in Cancer, vol. 116, n. 2, gennaio 2010, pp. 424–31, DOI:10.1002/cncr.24739, PMC 2811758, PMID 19918923.
Glaspy J, Atkins MB, Richards JM, et al., Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma, in Cancer, vol. 115, n. 22, novembre 2009, pp. 5228–36, DOI:10.1002/cncr.24576, PMID 19728370.
Augustine CK, Yoo JS, Potti A, et al., Genomic and molecular profiling predicts response to temozolomide in melanoma, in Clin. Cancer Res., vol. 15, n. 2, gennaio 2009, pp. 502–10, DOI:10.1158/1078-0432.CCR-08-1916, PMID 19147755.
Meije Y, Lizasoain M, García-Reyne A, et al., Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review, in Clin. Infect. Dis., vol. 50, n. 12, giugno 2010, pp. e73–6, DOI:10.1086/653011, PMID 20455691.
Liu R, Wang X, Ma B, Yang K, Zhang Q, Tian J, Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis, in Anticancer Drugs, vol. 21, n. 1, gennaio 2010, pp. 120–8, DOI:10.1097/CAD.0b013e32833304c5, PMID 19881333.
Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K, Temozolomide for high grade glioma, in Cochrane Database Syst Rev, n. 4, 2008, pp. CD007415, DOI:10.1002/14651858.CD007415, PMID 18843749.
Spiegel BM, Esrailian E, Laine L, Chamberlain MC, Clinical impact of adjuvant chemotherapy in glioblastoma multiforme : a meta-analysis, in CNS Drugs, vol. 21, n. 9, 2007, pp. 775–87, PMID 17696576.
Boogerd W, de Gast GC, Dalesio O, Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?, in Cancer, vol. 109, n. 2, gennaio 2007, pp. 306–12, DOI:10.1002/cncr.22411, PMID 17149755.
Stupp R, Tonn JC, Brada M, Pentheroudakis G, High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, in Ann. Oncol., 21 Suppl 5, maggio 2010, pp. v190–3, DOI:10.1093/annonc/mdq187, PMID 20555079.
(FR) Tilleul P, Brignone M, Hassani Y, et al., [Prescription guidebook for temozolomide usage in brain tumors], in Bull Cancer, vol. 96, n. 5, maggio 2009, pp. 579–89, DOI:10.1684/bdc.2009.0865, PMID 19467988.

oadoi.org

Stupp R, Mason WP, van den Bent MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, in N. Engl. J. Med., vol. 352, n. 10, marzo 2005, pp. 987–96, DOI:10.1056/NEJMoa043330, PMID 15758009.
Stupp R, Hegi ME, Mason WP, et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, in Lancet Oncol., vol. 10, n. 5, maggio 2009, pp. 459–66, DOI:10.1016/S1470-2045(09)70025-7, PMID 19269895.
Glas M, Happold C, Rieger J, et al., Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide, in J. Clin. Oncol., vol. 27, n. 8, marzo 2009, pp. 1257–61, DOI:10.1200/JCO.2008.19.2195, PMID 19188676.
Bromberg JE, van den Bent MJ, Oligodendrogliomas: molecular biology and treatment, in Oncologist, vol. 14, n. 2, febbraio 2009, pp. 155–63, DOI:10.1634/theoncologist.2008-0248, PMID 19182242.
Su Y, Amiri KI, Horton LW, et al., A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets, in Clin. Cancer Res., vol. 16, n. 1, gennaio 2010, pp. 348–57, DOI:10.1158/1078-0432.CCR-09-2087, PMID 20028756.
Glaspy J, Atkins MB, Richards JM, et al., Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma, in Cancer, vol. 115, n. 22, novembre 2009, pp. 5228–36, DOI:10.1002/cncr.24576, PMID 19728370.
Augustine CK, Yoo JS, Potti A, et al., Genomic and molecular profiling predicts response to temozolomide in melanoma, in Clin. Cancer Res., vol. 15, n. 2, gennaio 2009, pp. 502–10, DOI:10.1158/1078-0432.CCR-08-1916, PMID 19147755.
Meije Y, Lizasoain M, García-Reyne A, et al., Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review, in Clin. Infect. Dis., vol. 50, n. 12, giugno 2010, pp. e73–6, DOI:10.1086/653011, PMID 20455691.
Liu R, Wang X, Ma B, Yang K, Zhang Q, Tian J, Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis, in Anticancer Drugs, vol. 21, n. 1, gennaio 2010, pp. 120–8, DOI:10.1097/CAD.0b013e32833304c5, PMID 19881333.
Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K, Temozolomide for high grade glioma, in Cochrane Database Syst Rev, n. 4, 2008, pp. CD007415, DOI:10.1002/14651858.CD007415, PMID 18843749.
Boogerd W, de Gast GC, Dalesio O, Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?, in Cancer, vol. 109, n. 2, gennaio 2007, pp. 306–12, DOI:10.1002/cncr.22411, PMID 17149755.
Stupp R, Tonn JC, Brada M, Pentheroudakis G, High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, in Ann. Oncol., 21 Suppl 5, maggio 2010, pp. v190–3, DOI:10.1093/annonc/mdq187, PMID 20555079.
(FR) Tilleul P, Brignone M, Hassani Y, et al., [Prescription guidebook for temozolomide usage in brain tumors], in Bull Cancer, vol. 96, n. 5, maggio 2009, pp. 579–89, DOI:10.1684/bdc.2009.0865, PMID 19467988.

torrinomedica.it

Temodal, su torrinomedica.it. URL consultato il 20 gennaio 2011.
Temodal, su torrinomedica.it. URL consultato il 20 gennaio 2011.

web.archive.org

(EN) Jenerik TEMODAL geliyor! | Beyin Tümörü ve Tedavisi, su beyintumoru.org (archiviato dall'url originale il 4 gennaio 2011).
Temodar treatment for brain tumors, su temodar.com. URL consultato il 17 gennaio 2011 (archiviato dall'url originale il 2 febbraio 2011).

xagena.it

L’FDA ha approvato Temozolomide nel trattamento del glioblastoma multiforme, su xagena.it. URL consultato il 17 gennaio 2011.